New drugs for HIV infection.
The US Food and Drug Administration (FDA) has approved the marketing of five new drugs for treatment of HIV infection. Stavudine (D4T; Zerit -- Bristol-Myers Squibb) and lamivudine (3TC; Epivir -- Glaxo Wellcome) are nucleoside analogs similar to zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC). Saquinavir (Invirase -- Roche), ritonavir (Norvir -- Abbott) and indinavir (Crixivan -- Merck) are protease inhibitors, a new class of anti-HIV drugs.
D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir; D007546:Isoquinolines / Q000627:therapeutic use; D019259:Lamivudine; D011725:Pyridines / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D019438:Ritonavir; D019258:Saquinavir; D018119:Stavudine / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016047:Zalcitabine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D011725:Pyridines; D011804:Quinolines; D013844:Thiazoles; D019259:Lamivudine; D019469:Indinavir; D016047:Zalcitabine; D018119:Stavudine; D014633:Valine; D019258:Saquinavir; D019438:Ritonavir